Search results for " Adenosine A3"

showing 4 items of 4 documents

Induction of apoptosis in cardiac myocytes by an A3 adenosine receptor agonist.

1998

The effects of the selective adenosine (ADO) A3 receptor agonist IB-MECA (N6-(3-iodobenzyl)adenosine-5'-N-methylcarboxamide) on cultured newborn rat cardiomyocytes were examined in comparison with ADO, the ADO A1 receptor-selective agonist R-PIA (N6-R-phenylisopropyladenosine), or the ADO A3 selective antagonist MRS 1191 (3-ethyl-5-benzyl-2-methyl-6-phenyl-4-phenylethynyl-1, 4-(+/-)-dihydropyridine-3,5 dicarboxylate), using digital image analysis of Feulgen-stained nuclei. At high concentration, IB-MECA (/=10 microM ) and ADO (200 microM) induced apoptosis; however, R-PIA or MRS 1191 did not have any detectable effects on cardiac cells. In addition, DNA breaks in cardiomyocytes undergoing a…

AgonistContraction (grammar)TUNEL assayAdenosinemedicine.drug_classMyocardiumReceptor Adenosine A3ApoptosisHeartCell BiologyDNA FragmentationBiologyAdenosine receptorMolecular biologyAdenosineRatsApoptosismedicinePurinergic P1 Receptor AgonistsMyocyteAnimalsCalciumReceptorCells Culturedmedicine.drugExperimental cell research
researchProduct

Induction of Apoptosis in Rat Cardiocytes by A3 Adenosine Receptor Activation and Its Suppression by Isoproterenol

2000

The purpose of the present study was to investigate the mechanisms involved in the induction of apoptosis in newborn cultured cardiomyocytes by activation of adenosine (ADO) A3 receptors and to examine the protective effects of beta-adrenoceptors. The selective agonist for A3 ADO receptors Cl-IB-MECA (2-chloro-N6-iodobenzyl-5-N-methylcarboxamidoadenosine) and the antagonist MRS1523 (5-propyl-2-ethyl-4-propyl-3-(ethylsulfanylcarbonyl)-6-phenylpy rid ine-5-carboxylate) were used. High concentrations of the Cl-IB-MECA (or = 10 microM) agonist induced morphological modifications of myogenic cells, such as rounding and retraction of cell body and dissolution of contractile filaments, followed by…

Agonistmedicine.medical_specialtyProgrammed cell deathAdenosineCardiotonic Agentsmedicine.drug_classApoptosisStimulationBiologyInternal medicinePurinergic P1 Receptor AgonistsmedicineAnimalsProtein kinase AReceptorCells CulturedMyocardiumReceptor Adenosine A3IsoproterenolReceptors Purinergic P1HeartCell BiologyAdenosineAdenosine receptorRatsCell biologyEndocrinologyApoptosisSignal Transductionmedicine.drugExperimental Cell Research
researchProduct

Suppression of inflammation by low-dose methotrexate is mediated by adenosine A2A receptor but not A3 receptor activation in thioglycollate-induced p…

2005

Prior studies demonstrate that adenosine, acting at one or more of its receptors, mediates the anti-inflammatory effects of methotrexate in animal models of both acute and chronic inflammation. Both adenosine A2A and A3 receptors contribute to the anti-inflammatory effects of methotrexate treatment in the air pouch model of inflammation, and the regulation of inflammation by these two receptors differs at the cellular level. Because different factors may regulate inflammation at different sites we examined the effect of low-dose weekly methotrexate treatment (0.75 mg/kg/week) in a model of acute peritoneal inflammation in adenosine A2A receptor knockout mice and A3 receptor knockout mice an…

Mice KnockoutAdenosineDose-Response Relationship DrugReceptor Adenosine A2AReceptor Adenosine A3Anti-Inflammatory AgentsExudates and TransudatesPeritonitisDexamethasoneInterleukin-10MiceMethotrexateThioglycolatesAnimalsPeritoneumGlucocorticoidsResearch ArticleArthritis researchtherapy
researchProduct

A3 adenosine receptor: Homology modeling and 3D-QSAR studies

2012

Adenosine receptors (AR) belong to the superfamily of G-protein-coupled receptors (GPCRs). They are divided into four subtypes (A1, A2A, A2B, and A3) [1], and can be distinguished on the basis of their distinct molecular structures, distinct tissues distribution, and selectivity for adenosine analogs [2,3]. The hA3R, the most recently identified adenosine receptor, is involved in a variety of intracellular signaling pathways and physiological functions [4]. Expression of A3R was reported to be elevated in cancerous tissues [5], and A3 antagonists have been proposed for therapeutic treatments of cancer. The recent literature availability of crystal structure of hA2A adenosine receptor (PDB c…

Models MolecularQuantitative structure–activity relationshipReceptor Adenosine A2AAdenosine A3 Receptor AntagonistsQuantitative Structure-Activity RelationshipComputational biologyBiologyPharmacologyDrug DiscoveryMolecular dynamics simulationMaterials ChemistrymedicineHumansAmino Acid SequenceHomology modelingPhysical and Theoretical ChemistryReceptorA3 INHIBITORS HOMOLOGY MODELING 3D-QSARSpectroscopyG protein-coupled receptorA3 ReceptorBinding SitesTriazinesReceptor Adenosine A3Intracellular Signaling Peptides and ProteinsTriazolesA3 ADENOSINE RECEPTORComputer Graphics and Computer-Aided DesignAdenosine receptorAdenosineSettore CHIM/08 - Chimica FarmaceuticaPharmacophoresHomology modellingPharmacophoreProtein Bindingmedicine.drug
researchProduct